title: Linezolid does not show advantages over vancomycin in modulating the pulmonary immune response: how should we conciliate these new findings with the Zephyr trial results?
authors.forename: Andre C
authors.initials: AC
authors.lastname: Kalil
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D000069349:Linezolid; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D051379:Mice; D008807:Mice, Inbred BALB C; D023303:Oxazolidinones / Q000494:pharmacology*; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy* / Q000276:immunology*; D018570:Risk Assessment; D016896:Treatment Outcome; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D014640:Vancomycin; D000069349:Linezolid